Lu AG09222 (mAb)

About Lundbeck

Lundbeck is a Danish, publicly-traded biopharmaceutical leader with a century-long legacy, exclusively focused on central nervous system (CNS) disorders. Its strategy as a 'Focused Innovator' leverages deep, accumulated expertise in neuroscience to navigate the complexities of CNS drug development and commercialization. The company has built a significant global commercial footprint, particularly in the U.S., and maintains a robust pipeline aimed at addressing high-unmet-need conditions in psychiatry, neurology, and neuro-rare diseases, underpinned by a strong financial position with a market valuation of approximately $39 billion.

Therapeutic Areas

Other Migraine Prevention Drugs